An autologous tumor-derived heat shock protein vaccine for high risk ovarian cancer

Li, Z.; Nash, John D.; Ye, Qiao; Kulko, Judith M.; Wilcox, Diahann; Gaffney, Judith; Runowicz, Carolyn D.; Simonich, S. A.; Liu, B.; Srivastava, Pramod K.

doi:10.1200/jco.2005.23.16_suppl.9592

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our laboratory conducted a pilot study on the roles of the autologous ovarian cancer-derived gp96-peptide complex in the treatment of patients with stage III and IV ovarian cancer in the consolidation setting[ 52 ]. We hypothesized that effective immune intervention at the time of minimal residual disease is the ideal means to prevent relapses of this disease.…”

Section: Clinical Trials Of Immunotherapeutic Strategies Against Ovarmentioning

confidence: 99%

Ovarian cancer immunotherapy: opportunities, progresses and challenges

et al. 2010

View full text Add to dashboard Cite

Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer.

show abstract

Section: Clinical Trials Of Immunotherapeutic Strategies Against Ovarmentioning

confidence: 99%

Ovarian cancer immunotherapy: opportunities, progresses and challenges

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Patients underwent weekly vaccine administration at different dose levels [2.5 µg (n = 11); 25 µg (n = 16); 100 µg Advanced Phase I 15 [94] Glioma Recurrent high grade Phase I 12 [95] Recurrent Phase II 32 [107] Newly diagnosed Phase II 8 [96] Melanoma IV Phase I/II 36 [81,92] IV Phase II 39 [91] IV Phase III 322 [84] Renal cell IV Phase II 84 [96] I --IV Phase III 728 [97,98] Pancreatic I --III Phase I 10 [99] 9 [100] Ovarian III/IV Phase I 5 [101] Colorectal Adjuvant Phase II 29 [87] 15 [100] CML Chronic phase Phase I 14 [88] Lymphoma Low grade Phase II 10 [86,89] Low grade Phase II 20 [90] In all trials except chronic myelogenousleukemia (CML) the vaccine is HSPPC-96. In CML the vaccine is HSPPC-70.…”

Section: Phase I/ii Trial (C-100-02)mentioning

confidence: 99%

The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease

Pietro

Tosti

Ferrucci

et al. 2011

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents

Tosti

Cocorocchio

Pennacchioli

et al. 2014

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Melanoma, renal clear cell carcinoma, and glioblastoma are among suitable targets for HSP-based treatment as demonstrated by immune responses and clinical activity observed in subsets of patients, mainly those with early stage of disease and limited tumor burden. In order to further improve clinical activity, combinations of HSPPC-based vaccines with mutation-driven therapies, antiangiogenic agents, or immunomodulating monoclonal antibodies should be tested in controlled clinical trials.

show abstract

An autologous tumor-derived heat shock protein vaccine for high risk ovarian cancer

Cited by 5 publications

References 0 publications

Ovarian cancer immunotherapy: opportunities, progresses and challenges

Ovarian cancer immunotherapy: opportunities, progresses and challenges

The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease

Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents

Contact Info

Product

Resources

About